Home / Resource Library / Abstract CT244: HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkins lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)

Abstract CT244: HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkins lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)

AACR 2024

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Abstract CT244: HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkins lymphoma: primary results of a phase II study (HRAIN01-NHL01-II)